Epiretinal Radiation Therapy for Age-Related Macular Degeneration
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Blue Cross Blue Shield of North Carolina's coverage stance for intraocular radiation therapies (epiretinal brachytherapy, proton beam therapy, stereotactic radiotherapy) used to treat choroidal neovascularization from age-related macular degeneration and informs providers about coding and documentation. Applies to BCBSNC commercial members per the member benefit booklet.
No material clinical or coverage changes in this revision.
Coverage Criteria
Not covered (investigational) — Epiretinal/intraocular radiation therapies
Covered when ALL of the following are met
BCBSNC does not cover investigational services; no clinical coverage criteria are provided.
There is no applicable covered indication for epiretinal or intraocular radiation therapies for age-related macular degeneration (AMD). The policy explicitly lists “When Epiretinal Radiation Therapy for Age-Related Macular Degeneration is covered” as Not applicable, and therefore no clinical criteria for coverage are provided.
Because BCBSNC regards intraocular radiation therapies for choroidal neovascularization as investigational, these services are not covered. The policy states that intraocular placement of a radiation source (brachytherapy), proton beam therapy, and stereotactic radiotherapy for treatment of choroidal neovascularization are considered investigational, and notes that BCBSNC does not cover investigational services.
Coding and Billing
| Inclusion of a code in this section does not guarantee reimbursement; BCBSNC may require medical record review and prior determination of benefits. |
Provider Actions and Documentation
Coding and benefit determination
Inclusion of a code in this policy’s coding section does not guarantee reimbursement; services listed may require medical record review and prior benefit determination per the member’s benefit booklet and BCBSNC administrative policies.
Usual care context: anti-VEGF is standard; intraocular radiation is investigational
Standard treatment for neovascular (wet) AMD is intravitreal anti-VEGF agents (eg, pegaptanib, ranibizumab, bevacizumab, aflibercept) often requiring repeated injections; intraocular radiation modalities are investigational alternatives under study.
- Intraocular radiation modalities mentioned as investigational alternatives include epiretinal brachytherapy, proton beam therapy, and stereotactic radiotherapy.
Medical record documentation when requested
BCBSNC may request medical records to determine medical necessity; when records are requested include all specific information needed for that determination because letters of support or explanation alone are not sufficient unless they contain all required medical-necessity details.
- Provide complete medical records documenting clinical indications, prior treatments (including anti‑VEGF therapies), imaging, and procedural details as applicable.
Coverage denial risk: intraocular radiation therapies are investigational
Claims for intraocular placement of a radiation source (brachytherapy), proton beam therapy, or stereotactic radiotherapy to treat choroidal neovascularization will be denied because these services are considered investigational and BCBSNC does not cover investigational services.
- Do not expect coverage for epiretinal brachytherapy (intraocular radiation), proton beam therapy, or stereotactic radiotherapy for CNV due to AMD.
Background
Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults; the neovascular (wet) form is characterized by choroidal neovascularization (CNV) that can cause rapid and severe, often irreversible, central vision impairment. Standard management for neovascular AMD is intravitreal anti-VEGF therapy, typically administered as repeated injections. Intraocular radiation modalities — including epiretinal brachytherapy, proton beam therapy, and stereotactic radiotherapy — have been investigated as alternatives, but the policy concludes these approaches remain investigational for treatment of CNV related to AMD.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.